Demystifying the results obtained through the use of SGLT-2 inhibitor drugs, used by patients at the Reference Center for Hypertension and Diabetes Rio Verde - Goiás
Authors:
- Luan Queiroz Fernandes PereiraLPLuan Queiroz Fernandes Pereira
- Thamires Ferreira dos SantosTSThamires Ferreira dos Santos
- Rodrigo Jacques da SilvaRSRodrigo Jacques da Silva
- Hortência Thales Padilha GomesHGHortência Thales Padilha Gomes
- Júlia Lenza GoulartJGJúlia Lenza Goulart
- João Felipe Cardoso CarvalhoJCJoão Felipe Cardoso Carvalho
- Lucas Almeida Azevedo CarlosLCLucas Almeida Azevedo Carlos
Open Access
- 8 November 2023
- journal article
- abstracts
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (12)
Abstract
Introduction: Due to the increase in glucose excretion of renal sodium-glucose cotransporter 2 (ISGLT-2) inhibitors, there is also a reduction in weight through its glycosuric effect. Objective: To analyze the efficacy of ISGLT-2 based on medical records and glycemic levels according to glycated blood glucose; to verify which medications are most prescribed and to observe poor adherence due to side effects in patients of the CRHD in Rio Verde-GO. Methods: A descriptive observational study was carried out using the medical records of diabetic patients treated at the CRHD as the main means of data collection, identifying and comparing laboratory values based on the different pharmacological conducts performed. And manually organize and group the search results on the Excel platform, where they will later be converted into easy-to-view graphs for the public. Results And Discussion: When analyzing the glycated hemoglobin (HbA1c) of the patients before and after the introduction of the ISGLT-2 class, it was noted that 80% obtained a laboratory improvement and 20% a worsening. The results reveal that 80% had an improvement in glycated hemoglobin, as they presented good adherence to the medication and specific and balanced nutrition for their condition. Conclusion: There is an improvement in glycated hemoglobin in most of the patients treated at the CRHD who are users of iSGLT-2, where the most used medication is Forxiga (Dapaglifozin), which is part of the medications of the SUS network.Keywords
This publication has 15 references indexed in Scilit:
- Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in DiabetesJACC, 2018
- Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitusIndian Heart Journal, 2018
- Development of SGLT1 and SGLT2 inhibitorsDiabetologia, 2018
- Type 2 diabetesThe Lancet, 2018
- Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectivesDiabetes/Metabolism Research and Reviews, 2017
- Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials 艾格列净治疗2型糖尿病:基于3期试验的安全性与有效性概述Journal of Diabetes, 2015
- Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year dataDiabetes, Obesity and Metabolism, 2015
- Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2Medicina Clinica, 2013
- Da relevância dos estudos observacionaisRevista Brasileira de Reumatologia, 2007
- Glico-hemoglobina (HbA1c): aspectos clínicos e analíticosArchives of Endocrinology and Metabolism, 2004